Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors

Previous studies have established the rationale for NK105, a nanomicellar formulation of paclitaxel, administered every 3 weeks. The aim of this phase I study was to determine the recommended dose and pharmacokinetics of weekly administered NK105. NK105 was administered by a 30-min infusion once wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Hirofumi, Kato, Ken, Esaki, Taito, Ohsumi, Shouzou, Hozomi, Yasuo, Matsubara, Nobuaki, Hamaguchi, Tetsuya, Matsumura, Yasuhiro, Goda, Rika, Hirai, Takayuki, Nambu, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099351/
https://www.ncbi.nlm.nih.gov/pubmed/27595901
http://dx.doi.org/10.1007/s10637-016-0381-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099351/
https://www.ncbi.nlm.nih.gov/pubmed/27595901
http://dx.doi.org/10.1007/s10637-016-0381-4

Ejemplares similares